Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Bayer Aktiengesellschaft American Depositary Shares (OP: BAYRY)
108.13 USD  -0.59 (-0.54%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about Bayer Aktiengesellschaft American Depositary Shares
 
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Bayer Looks To Expand Xarelto Label (revised)
January 03, 2012
Bayer (BAYRY) and partner Janssen Research and Development (JRD) are seeking approval to market their co-developed blood thinner, Xarelto, to reduce the risk of cardiovascular events in patients... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
10 Best 401k Plans in America
January 03, 2012
 Read More
category 401k & Investing Tips , NYSE:NVS , NYSE:LUV , and 2 more.
from InvestorPlace - Latest Headlines
Bayer Seeks To Expand Xarelto’s Label
January 03, 2012
Bayer (BAYRY) recently announced that it has filed an application with the US Food and Drug Administration (FDA) seeking approval to market its blood thinner, Xarelto, in the US to reduce the risk of... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Huntsman Is Priced To Move (HUN, LYB, BASFY, BAYRY, DOW)
December 27, 2011
Huntsman trades below $10 for the first time since 2009. Prior to 2009, it had never dropped into single digits. It's priced to move. Read More
from Investopedia Advisor Commentary
Bayer Seeks European Approval
December 23, 2011
Bayer  (BAYRY) recently announced that it has filed an application with the European Medicines Agency (EMA) seeking approval to market its blood thinner, Xarelto, in the EU for secondary prevention... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Pipeline Setback At Bristol-Myers
December 23, 2011
Bristol-Myers Squibb Company (NYSE:BMY) recently suffered a pipeline setback with its oncology candidate, brivanib, performing disappointingly in a late-stage study (BRISK-PS). The study evaluated... Read More
category SNY , Stocks , External Research , and 3 more.
from DailyMarkets.com
Bayer Upped To Neutral
December 20, 2011
We have upgraded our recommendation on Bayer (BAYRY) from Underperform to Neutral. Our target price on the stock is $61.00. The US approval of blood thinner Xarelto for the highly lucrative atrial... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Europe stocks edge up, led by Lanxess, Rio Tinto
December 16, 2011
Europe stocks rise Friday but are still poised for weekly losses. Lanxess gains on a broker upgrade and miners also contribute to gains. Read More
category BCS , Banks , Transportation Equipment , and 34 more.
from MarketWatch
Micromet’s Blinatumomub Data At ASH
December 13, 2011
Micromet Inc. (NASDAQ:MITI) recently presented encouraging data from a mid-stage study of its lead pipeline candidate blinatumomab in adults suffering from relapsed or refractory B-precursor acute... Read More
category AZN , RHHBY , External Research , and 7 more.
from DailyMarkets.com
Watson’s Generic Launches Continue
December 09, 2011
Watson Pharmaceuticals Inc. (NYSE:WPI) recently announced the launch of a generic version of Teva Pharmaceutical Industries Ltd.‘s (NASDAQ:TEVA) LoSeasonique. The drug is used for the prevention of... Read More
category jnj , TEVA , WPI , and 5 more.
from DailyMarkets.com
Risk-Reward Balanced At Onyx Pharma
December 08, 2011
We continue to have a Neutral recommendation on Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), which posted a loss of 44 cents per share in the third quarter 2011. While the Zacks Consensus Estimate was... Read More
category ONXX , Stocks , External Research , and 2 more.
from DailyMarkets.com
Regeneron’s Eylea Data Unimpressive
December 07, 2011
Recently, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and partner Bayer (BAYRY) presented not very encouraging two-year data from a couple of parallel late-stage studies (VIEW 1 and VIEW 2) of their... Read More
category NVS , REGN , Stocks , and 3 more.
from DailyMarkets.com
Micromet Begins New Trial
December 05, 2011
Micromet Inc. (NASDAQ:MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory... Read More
category AZN , External Research , Contributor , and 5 more.
from DailyMarkets.com
Watson Brings Lipitor’s Generic
December 01, 2011
In what seems like one of the biggest generic launches in the history of US, Watson Pharmaceuticals, Inc. (NYSE:WPI) announced the launch of an authorized generic version of Pfizer Inc.’s (NYSE:PFE)... Read More
category WPI , Stocks , External Research , and 3 more.
from DailyMarkets.com
Regeneron Seeks Label Expansion
November 25, 2011
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), which is looking to expand the label of its drug Arcalyst into the gout indication, recently announced that the US Food and Drug Administration (FDA) has... Read More
category REGN , Stocks , External Research , and 2 more.
from DailyMarkets.com
(JNJ) Bayer Cut to Underperform
November 23, 2011
We recently downgraded Bayer (BAYRY) to Underperform from Neutral purely on valuation grounds. We... Visit StockBlogHub to view complete post. Read More
category JNJ , Healthcare , Johnson & Johnson , and 1 more.
from Stock Blog Hub
Bayer Cut To Underperform
November 22, 2011
We recently downgraded Bayer (BAYRY) to Underperform from Neutral purely on valuation grounds. We believe that the stock is overvalued at current levels. Even though the US Food and Drug Administration... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Regeneron Drug Cleared In The US
November 21, 2011
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) recently received a huge boost when the US Food and Drug Administration (FDA) cleared its injectable eye drug Eylea (aflibercept) for treating patients... Read More
category NVS , REGN , Stocks , and 3 more.
from DailyMarkets.com
Sanofi’s MS Candidate Advances
November 17, 2011
Sanofi’s (NYSE:SNY) subsidiary Genzyme (acquired in April 2011) recently announced encouraging data on its phase III candidate, Lemtrada (alemtuzumab). Results were presented from the phase III CARE-MS... Read More
category MKGAF , SNY , Stocks , and 3 more.
from DailyMarkets.com
Micromet Loss Widens, Revs Let Down
November 09, 2011
Micromet Inc.’s (NASDAQ:MITI) third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 13 cents per share (also... Read More
category AZN , External Research , Contributor , and 5 more.
from DailyMarkets.com
Higher Costs Push Up Loss At Ardea
November 08, 2011
Ardea Biosciences Inc.’s (NASDAQ:RDEA) third quarter 2011 net loss of 84 cents per share exceeded the year-ago loss by 5 cents and the Zacks Consensus loss Estimate by 17 cents. The wider loss was... Read More
category RDEA , Stocks , External Research , and 2 more.
from DailyMarkets.com
Onyx’s Loss Widens, Misses Revenues
November 03, 2011
Onyx Pharmaceuticals Inc.’s (NASDAQ:ONXX) third quarter 2011 loss of 44 cents per share came in 6 cents wider than the Zacks Consensus Estimate. In the year-ago quarter the company had reported... Read More
category ONXX , Stocks , External Research , and 2 more.
from DailyMarkets.com
Revenues Rise At Bayer
November 03, 2011
Bayer’s (BAYRY) earnings per share during the third quarter of 2011 came in at €1.12 (approx. $1.58) compared to €0.95 (approx. $1.22) in the year-ago period. Higher revenues boosted earnings. The... Read More
category Stocks , External Research , Contributor , and 1 more.
from DailyMarkets.com
Higher Costs Push Up Loss At Regeneron
November 01, 2011
Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) third quarter 2011 net loss of $0.68 per share was wider than the year-ago loss of $0.41 per share. The wider year over year loss suffered by the company... Read More
category AZN , REGN , SNY , and 4 more.
from DailyMarkets.com
Sigma Surpasses EPS Estimates
October 25, 2011
Sigma-Aldrich Corporation (NASDAQ:SIAL) delivered third-quarter earnings of 96 cents per share, surpassing the Zacks Consensus Estimate of 91 cents per share and an increase of 16% year over year. The... Read More
category SIAL , Stocks , External Research , and 2 more.
from DailyMarkets.com
Onyx And Bayer Bury The Hatchet
October 13, 2011
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently settled its dispute and modified its deal with partner Bayer (BAYRY) regarding their cancer drug Nexavar and Bayer’s cancer candidate regorafenib. The... Read More
category ONXX , Stocks , External Research , and 2 more.
from DailyMarkets.com
Bayer’s Cancer Candidate Encourages
October 03, 2011
Bayer (BAYRY) presented encouraging final data from a late-stage study (ALSYMPCA: n=922) on its cancer candidate alpharadin. The late-stage study evaluated the candidate for treating... Read More
category Stocks , External Research , Contributor , and 2 more.
from DailyMarkets.com
EU Backs Bayer/JNJ’s Xarelto
September 28, 2011
Recently Bayer (BAYRY) and partner Johnson & Johnson (NYSE:JNJ) announced that the European Committee for Medicinal Products for Human Use (CHMP) has recommended their blood-thinner (anticoagulant)... Read More
category SNY , jnj , Stocks , and 4 more.
from DailyMarkets.com
Bayer Evenly Poised
September 16, 2011
We are maintaining our Neutral recommendation on Germany’s Bayer (BAYRY) with a target price of $56.00. Headquartered in Leverkusen, Germany, Bayer is one of the world’s largest healthcare and chemical... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Risk-Reward Balanced At Micromet
September 12, 2011
We have maintained a Neutral rating on Micromet, Inc. (NASDAQ:MITI) with a target price of $5.00 per share. We believe Micromet’s lead pipeline candidate, blinatumomab, holds tremendous potential in... Read More
category AZN , External Research , Contributor , and 5 more.
from DailyMarkets.com
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here